Clinical trials: Oncologic Complications
PORTs/Peripheral IVs Complication Rates
Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs
This study is to collect current information on complications rates of subjects undergoing chemotherapy administration through Ports and peripheral IVs.
- Trial name
- VEINSFORLIFE (NCT02792764)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- C. R. Bard
Solid Tumor, Metastatic Bladder Cancer
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1).
- Trial name
- NCT02030067
- Testing
- RX-3117
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Processa Pharmaceuticals